Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients

Exclusion Criteria

• •A potential subject who meets any of the following criteria will be excluded from participation in this study:
• •Carrier of a known clinically relevant DPYD variant (i.e. \*2A, \*7, \*13, c.1236G\>A or c.2846A\>T);
• •Any medical condition that is known to influence capecitabine absorption (i.e. a Roux-en-Y gastric bypass operation or complete gastric resection; an esophagectomy is not considered to impair absorption);
• •Prior treatment with fluoropyrimidines;
• •Use of DPD-inhibitors and/or allopurinol;
• •Known pregnancy at baseline.